Cholesterol measures to identify and treat individuals at risk for coronary heart disease

American Journal of Preventive Medicine

Volumn 25, Issue 1, 2003, Pages 50-57

  Natarajan, Sundar ^a,b,f   Glick, Henry ^c   Criqui, Michael ^d   Horowitz, David ^c   Lipsitz, Stuart R ^e   Kinosian, Bruce ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f Medical University of South Carolina ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; MONITORING; PREDICTION;

EID: 0037671266     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(03)00092-8     Document Type: Article

References (36)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA. 285:2001;2486-2497.
2. Rubins H.B., Robins S.J., Collins D., et al. Distribution of lipids in 8500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol. 75:1995;1196-1201.
3. Genest J.J., McNamara J.R., Salem D.N., Schaefer E.J. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 67:1991;1185-1189.
4. Goldbourt U., Yaari S., Medalie J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 17:1997;107-113.
5. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79:1989;8-15.
6. Stampfer M.J., Krauss R.M., Ma J., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:1996;882-888.
7. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level a meta-analysis of population-based prospective studies . J Cardiovasc Risk. 3:1996;213-219.
8. Gaziano J.M., Hennekens C.H., O'Donnell C.J., Breslow J.L., Buring J.E. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 96:1997;2520-2525.
9. Grundy S.M., Vega G.L. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med. 152:1992;28-34.
10. Tato F., Vega G.L., Grundy S.M. Determinants of plasma HDL-cholesterol in hypertriglyceridemic patients. Role of cholesterol-ester transfer protein and lecithin cholesteryl acyl transferase. Arterioscler Thromb Vasc Biol. 17:1997;56-63.
11. Kinosian B., Glick H., Preiss L., Puder K.L. Cholesterol and coronary heart disease predicting risks in men by changes in levels and ratios . J Investig Med. 43:1995;443-450.
12. Kinosian B., Glick H., Garland G. Cholesterol and coronary heart disease predicting risks by levels and ratios . Ann Intern Med. 121:1994;641-647.
13. Anderson K.M., Wilson P.W., Odell P.M., Kannel W.B. An updated coronary risk profile. A statement for health professionals. Circulation. 83:1991;356-362.
14. Grover S.A., Coupal L., Hu X.P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA. 274:1995;801-806.
15. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 325:1991;373-381.
16. Dawber T.R., Meadors G.F., Moore F.E. Epidemiologic approaches to heart disease. The Framingham Study. Am J Public Health. 41:1951;279-286.
17. Shurtleff D. Some characteristics related to the incidence of cardiovascular disease and death: Framingham Heart Study 18-year follow-up. In: Kannel WB, Gordon T, eds. The Framingham Study: an epidemiological investigation of cardiovascular disease, section 30. Washington DC: U.S. Government Printing Office, 1974:17-25.
18. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 251:1984;351-364.
19. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 251:1984;365-374.
20. Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial. J Chronic Dis. 36:1983;467-479.
21. Abbott RD, McGee D. The probability of developing certain cardiovascular diseases in eight years at specified values of certain characteristics: the Framingham Study. In: Kannel WB, Wolf PA, Garrison RJ, eds. The Framingham Study: an epidemiological investigation of cardiovascular disease, section 37. Springfield VA: National Technical Information Service, 1987.
22. Landis J.R., Heyman E.R., Koch G.G. Average partial association in three-way contingency tables A review and discussion of alternative tests . Int Stat Rev. 46:1978;237-254.
23. Ridker P.M. Evaluating novel cardiovascular risk factors can we better predict heart attacks? Ann Intern Med. 130:1999;933-937.
24. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 97:1998;2007-2011.
25. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 341:1999;410-418.
26. Manninen V., Elo M.O., Frick M.H., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 260:1988;641-651.
27. Jacobson T.A. "The lower the better" in hypercholesterolemia therapy a reliable clinical guideline? Ann Intern Med. 133:2000;549-554.
28. Grundy S.M. Statin trials and goals of cholesterol-lowering therapy. Circulation. 97:1998;1436-1439.
29. Gotto A.M. Jr, Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 101:2000;477-484.
30. Law M.R., Wald N.J., Wu T., Hackshaw A., Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies data from the BUPA study . BMJ. 308:1994;363-366.
31. Sacks F.M., Handysides G.H., Marais G.E., Rosner B., Kass E.H. Effects of a low-fat diet on plasma lipoprotein levels. Arch Intern Med. 146:1986;1573-1577.
32. Very low-calorie diets. JAMA. 270:1993;967-974.
33. Lichtenstein A.H., Ausman L.M., Jalbert S.M., Schaefer E.J. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med. 340:1999;1933-1940.
34. Ballantyne C.M., Olsson A.G., Cook T.J., Mercuri M.F., Pedersen T.R., Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 104:2001;3046-3051.
35. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) . JAMA. 288:2002;2998-3007.
36. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER) a randomised controlled trial . Lancet. 360:2002;1623-1630.